IL18 and Miyoshi myopathy: Analyzing the modulation of NKG2D activating receptor expression on CD3−CD56+ NK cells and their CD3−CD56dim+ and CD3−CD56bright+ subsets with all investigated cytokines we show that both percentage and MFI of this receptor decrease significantly (p < 0.05, Wilcoxon signed rank test) only in MM patients after 18 h in vitro treatment with IL-18 on NK cells, as well as on their dim subset.